Beat the Odds in CNS Drug Development

CNS Drug Development Is Expensive — Avoid Costly Failures

Cytel is at the forefront of CNS drug development. Our solutions and proven expertise can guide you through the unique challenges faced within CNS drug development:

• ​Unreliable Preclinical Models — Many animal models fail to replicate human CNS diseases, limiting their predictive value.
• Difficult Clinical Measurements — Difficult clinical measurements lead to a reliance on surrogate endpoints.
• Patient Adherence Issues — Cognitive and physical impairments make it harder for patients to follow treatment regimens.
• Subjective and Variable Assessments — Many CNS measures lack standardization, are prone to bias, and reduce data reliability.
• Need for Early Validation — Strong Proof of Mechanism (PoM) and Proof of Concept (PoC) are essential to de-risk late-stage failures.